TV News LIES

An obesity drug called Zepbound won approval for use in adults from the Food and Drug Administration Wednesday, ushering in a new rival to Novo Nordisk's blockbuster Wegovy.

Eli Lilly & Co., maker of Zepbound, says it shows greater weight loss at a lower list price than Wegovy. The Lilly drug will be available in the U.S. by the end of the year. A version of the shot, known generically as tirezepatide, is already sold as Mounjaro to treat Type 2 diabetes.

The Lilly drug works by acting on two hormone receptors in the brain, including one called GLP-1, short for glucagon-like peptide-1 – that regulate appetite and metabolism.

The new class of medicines for managing obesity that includes Zepbound and Wegovy has given people with obesity and overweight a potent option for treatment. But the drugs are expensive, and many people who lose weight regain it after stopping the medicines.

More...

What if the song "Baby Shark" stopped after just two stanzas?

For non-fans of the catchy tune, that might sound like a dream. For a real-life Mommy Shark in Illinois, it's reality: She produced a baby without a Daddy Shark.

The epaulette shark pup hatched this summer at Brookfield Zoo, just west of Chicago. Its mother has been at the zoo since 2019; in that time, she's never shared a tank with a male.

It's a rare case of parthenogenesis, a type of asexual reproduction, according to the zoo.

The US chemical industry likely spent over $110m during the last two election cycles deploying lobbyists to kill dozens of pieces of PFAS legislation and slow administrative regulation around “forever chemicals”, a new analysis of federal lobbying documents has found.

The industry’s onslaught was effective: only eight pieces of legislation that targeted PFAS made it through Congress, the paper prepared by the Food and Water Watch (FWW) nonprofit found.

“There’s an extreme amount of money that’s going into fighting [PFAS legislation],” said Amanda Starbuck, FWW’s research director and the lead author on the report. “It’s hard to win these fights when there’s so much funding being put in from the opposing side.”

The highly anticipated testimony of former President Trump in his New York civil fraud trial Monday heaved chaotically between defending his business practices and decrying those involved in the case as politically motivated “Trump haters.”

Months of bubbling tensions between Trump and New York Judge Arthur Engoron reached a boiling point in the courtroom almost as soon as the real estate mogul took the witness stand, with the judge at one point asking Trump’s lawyer to control his client.